drugset / Trial / NCT00075218

A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

NCT00075218

Phase 3 Completed 361 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.

Timeline

Start
2003-12
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sunitinib Small molecule 50 mg Oral